1. Home
  2. TBPH vs VSTM Comparison

TBPH vs VSTM Comparison

Compare TBPH & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • VSTM
  • Stock Information
  • Founded
  • TBPH 2013
  • VSTM 2010
  • Country
  • TBPH United States
  • VSTM United States
  • Employees
  • TBPH N/A
  • VSTM N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • VSTM Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBPH Health Care
  • VSTM Health Care
  • Exchange
  • TBPH Nasdaq
  • VSTM Nasdaq
  • Market Cap
  • TBPH 699.0M
  • VSTM 581.6M
  • IPO Year
  • TBPH N/A
  • VSTM 2012
  • Fundamental
  • Price
  • TBPH $18.81
  • VSTM $10.08
  • Analyst Decision
  • TBPH Strong Buy
  • VSTM Strong Buy
  • Analyst Count
  • TBPH 4
  • VSTM 9
  • Target Price
  • TBPH $24.25
  • VSTM $13.38
  • AVG Volume (30 Days)
  • TBPH 569.5K
  • VSTM 2.8M
  • Earning Date
  • TBPH 11-10-2025
  • VSTM 11-04-2025
  • Dividend Yield
  • TBPH N/A
  • VSTM N/A
  • EPS Growth
  • TBPH N/A
  • VSTM N/A
  • EPS
  • TBPH 0.58
  • VSTM N/A
  • Revenue
  • TBPH $80,327,000.00
  • VSTM $13,379,000.00
  • Revenue This Year
  • TBPH $79.82
  • VSTM $88.60
  • Revenue Next Year
  • TBPH N/A
  • VSTM $416.99
  • P/E Ratio
  • TBPH $32.54
  • VSTM N/A
  • Revenue Growth
  • TBPH 27.12
  • VSTM 33.79
  • 52 Week Low
  • TBPH $7.90
  • VSTM $3.46
  • 52 Week High
  • TBPH $18.96
  • VSTM $11.25
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 68.84
  • VSTM 63.40
  • Support Level
  • TBPH $17.50
  • VSTM $7.29
  • Resistance Level
  • TBPH $18.58
  • VSTM $10.45
  • Average True Range (ATR)
  • TBPH 0.99
  • VSTM 0.67
  • MACD
  • TBPH 0.16
  • VSTM 0.21
  • Stochastic Oscillator
  • TBPH 98.49
  • VSTM 93.35

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: